 | Up a level |
Fowler, Nathan Hale, Dickinson, Michael, Dreyling, Martin, Martinez-Lopez, Joaquin, Kolstad, Arne, Butler, Jason 
ORCID: 0000-0002-6422-4404, Ghosh, Monalisa, Popplewell, Leslie, Chavez, Julio C., Bachy, Emmanuel, Kato, Koji, Harigae, Hideo, Kersten, Marie Jose, Andreadis, Charalambos, Riedell, Peter A., Ho, P. Joy, Perez-Simon, Jose Antonio, Chen, Andy, I, Nastoupil, Loretta J., von Tresckow, Bastian, Ferreri, Andres Jose Maria, Teshima, Takanori, Patten, Piers E. M., McGuirk, Joseph P., Petzer, Andreas L., Offner, Fritz, Viardot, Andreas, Zinzani, Pier Luigi, Malladi, Ram, Zia, Aiesha, Awasthi, Rakesh, Masood, Aisha, Anak, Oezlem, Schuster, Stephen J. and Thieblemont, Catherine
(2022).
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial.
Nat. Med., 28 (2).
S. 325 - 343.
BERLIN:
NATURE PORTFOLIO.
ISSN 1546-170X
Jaeger, Ulrich, Worel, Nina, McGuirk, Joseph, Riedell, Peter A., Fleury, Isabelle, Borchmann, Peter, Du, Yan, Abdelhady, Ahmed M., Han, Xia, Martinez-Prieto, Marcela and Waller, Edmund K. (2021). Safety and efficacy of tisagenlecleucel (tisa-cel) plus pembrolizumab (pembro) in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL): Updated analysis of the phase 1b PORTIA study. J. Clin. Oncol., 39 (15). PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 1527-7755